Oncology Marketing Consultant & Advisor for Cancer Practices, Centers & Programs
Cancer care is one of the few markets where a search query can begin with fear, move through molecular biology, insurance, physician reputation, geography and family logistics, then end with a decision that nobody wanted to have to make. I help oncology organizations make the path to credible information and appropriate care clearer without turning a serious diagnosis into a sales funnel with nicer typography.
The short version for a very complicated specialty.
Oncology growth is a coordination problem disguised as a marketing problem. Patients, caregivers, primary-care physicians, surgeons, radiologists, pathologists, subspecialists, hospitals, payers and research teams may all influence the same episode of care.
- Discovery has to be disease-specific. “Cancer care” is too broad to explain why a particular physician, program or center belongs in the conversation.
- Referral growth is relational and operational. A beautiful campaign cannot repair a referral path that takes four phone calls and a fax scavenger hunt.
- Clinical authority has to stay clinical. Marketing can explain expertise, access and evidence. It should never invent candidacy, prognosis or certainty.
- AI search changes the front door. More patients and families ask long, anxious, specific questions before they ever reach a hospital website.
- Capacity matters. Growth without infusion chairs, physician access, navigation, records workflows or treatment capacity can make patient experience worse.
- The useful metric is appropriate care reached. Clicks are supporting evidence, not the ending.
Oncology rewards people who understand the whole system.
The page is long because the market is. Skip to the part creating trouble.
Oncology is not one buying decision. It is a chain of decisions made under pressure.
A new cancer diagnosis compresses time. The person searching may have a pathology report open in another tab, a spouse asking questions from across the kitchen, a primary-care doctor recommending one system, a surgeon recommending another specialist and an insurance portal that appears to have been designed by somebody with a personal grudge against clarity.
That context changes what good marketing looks like. The normal commercial instinct is to make the organization look impressive. The better oncology instinct is to make the organization understandable. Who treats this cancer? How specialized is the program? Is this location appropriate? Does the team offer medical oncology, radiation, surgery, infusion, genetics, supportive care or trials? Can somebody review outside records? What is the second-opinion process? Which questions belong to a clinician?
The American Cancer Society currently estimates 2,114,850 new cancer cases and 626,140 cancer deaths in the United States in 2026. Those numbers describe population burden, not a marketing opportunity forecast, but they explain why cancer discovery and access touch nearly every major healthcare market. American Cancer Society Cancer Statistics Center.
I am a strategist, not an oncologist. My job is to understand the business around the medicine deeply enough to help the right information, physician, program and access pathway reach the right audience. Diagnosis, treatment and prognosis remain where they belong: with qualified clinical professionals.
A cancer program can contain half a dozen different markets before lunch.
The word “oncology” hides meaningful differences in patient journey, referral source, technology, revenue, geography and clinical decision-making. I would rather map those differences first than flatten everything into a generic cancer-service campaign.
Systemic therapies, infusion, chronic treatment relationships, pharmacy and drug economics, navigation, laboratory data, referrals and longitudinal care.
Technology-intensive care, physician referrals, site convenience, treatment schedules, planning, specific disease programs and coordination with surgeons and medical oncologists.
Organ-specific expertise, complex procedures, hospital relationships, second opinions, multidisciplinary evaluation and regional or tertiary referral patterns.
Leukemia, lymphoma, myeloma and related programs where subspecialty authority, advanced therapies, transplantation relationships and trial access can shape discovery.
Molecular testing, germline and somatic information, tumor boards, pathology, treatment selection and a communication burden that increases every time the science gets better.
Nutrition, rehabilitation, psychosocial support, symptom management, palliative care, survivorship services and the long tail of life after active treatment.
The practical lesson is simple: a lung-cancer program, breast center, prostate-cancer program, melanoma clinic and leukemia program should not all sound like alternate skins on the same template. The decision pathways are different, so the public explanation should be different too.
Community practices can win by being excellent at being community practices.
Independent and community oncology groups operate in a market with enormous institutional brands. Trying to out-university a university cancer center is usually a poor use of pixels.
A community practice may have very different strengths: earlier appointment access, continuity with one medical oncologist, local infusion, familiar staff, convenient parking, relationships with primary-care physicians, coordination with nearby hospitals, proximity to a patient's support network and the ability to keep appropriate care close to home.
Those advantages have to be real. Marketing should document them, not manufacture them. If the practice refers complex surgery, transplant, rare-disease care or trials to tertiary centers, that can be presented as thoughtful coordination rather than a weakness. Patients do not need every capability under one roof. They need confidence that somebody understands what should happen next.
The broad Physician & Surgeon Marketing page owns general medical-practice growth. This specialist page goes deeper into the referral, treatment, research and navigation realities unique to oncology.
A cancer center has to make a complex institution legible to a person who did not study the org chart.
Large cancer programs often have remarkable capabilities trapped inside departmental language. The patient thinks in diseases and decisions. The institution thinks in departments, institutes, divisions, service lines, faculty, locations, research groups and scheduling pools.
The website has to translate between those worlds.
A useful cancer-center experience can let somebody begin with breast cancer, pancreatic cancer, lymphoma or brain tumor, understand the relevant specialists and treatments, see whether a multidisciplinary program exists, learn how second opinions work, discover active research, understand geography and then take the next appropriate step.
NCI currently lists 74 NCI-Designated Cancer Centers in its directory. Designation is a specific research-focused institutional status, not a generic synonym for “good cancer center,” and public claims should mirror the organization's actual status. NCI cancer-center directory.
If the problem is enterprise health-system strategy across many service lines, facilities and audiences, my Hospital & Health System Marketing work owns that broader problem. Here, I am staying inside oncology.
Oncology referrals move through trust networks before they move through software.
A referral is rarely “a lead.” It is a professional judgment, a patient handoff, a records problem, a scheduling event and often a relationship that somebody wants preserved.
Referral marketing should answer practical questions a professional office actually has: Who sees this diagnosis? What records are required? Is an urgent slot available? Which location? Can the receiving team review imaging or pathology? Does the patient need authorization first? Who can the referrer call when the ordinary path is too slow?
A glossy physician brochure cannot compensate for a referral process that eats information. The best outreach program in the world eventually has to survive contact with the fax machine.
People rarely search “oncology” when the question in their head is much more specific.
Real oncology search is full of detail: “pancreatic cancer second opinion,” “oncologist for triple negative breast cancer,” “radiation oncology near me,” “CAR T center,” “prostate cancer specialist,” “hematologist for myeloma,” “can I get chemo closer to home,” “who treats rare sarcoma,” or the quieter search that starts with a physician's name after another doctor writes it on a piece of paper.
That creates a content model organized around diseases, physicians, programs, treatments, locations, questions and relationships. It also creates a quality obligation. Health information can rank and still be poor. The goal is to make the right page useful enough that a patient or referrer understands what the program actually does and what to do next.
Local discovery matters differently across oncology services. Daily radiation can make travel burden extremely important. Infusion convenience may shape community care. Rare tumors, transplantation, complex surgery or research can support a much larger regional or national draw. Geography should follow the service rather than being stuffed into every heading.
For the deeper search system connecting SEO, GEO, answer-focused content and AI discovery, see my AI Search & Organic Growth work.
The patient may ask an AI system a twenty-line question before visiting a single cancer-center website.
A conventional keyword plan imagines a person typing a short phrase. A real cancer conversation can look more like: “My father is 72, newly diagnosed with stage III lung cancer, lives two hours from the city and wants a second opinion. What kind of specialist should he see and what records should he bring?”
An answer system has to assemble concepts: disease, stage, specialist type, second opinion, geography, age, records, possibly treatment modalities and sometimes clinical trials. If the organization's public information is vague, fragmented or hidden behind departmental language, the system has less reliable material to work with.
Make physician names, specialties, cancer types, programs, locations and institutional relationships explicit.
Answer the questions patients and caregivers actually ask, including logistical ones that traditional service pages ignore.
Connect current medical claims to authoritative sources and clinical review instead of letting marketing prose improvise science.
Give answer systems accurate next steps: appointment, referral, second opinion, records, location and emergency boundaries.
No serious person can promise that ChatGPT, Gemini, Google or another system will quote a particular page. I can improve the conditions for comprehension, retrieval and trust. The rest remains an external system making its own decisions.
Oncology content has to be clinically useful enough to earn attention and commercially clear enough to help someone act.
Many cancer websites fail in one of two directions. Some are technically correct but written like an internal reference manual. Others are friendly but so general that a patient cannot tell whether the organization treats the diagnosis at all.
Disease pages
Explain the cancer type, the relevant specialists and services, how evaluation works, treatment categories the program actually offers, research connections where real, and the route into care. Medical claims should be reviewed and updated.
Physician pages
Show the actual focus: diseases treated, procedures, training, research, publications, affiliations and locations. A physician biography should help a patient understand fit, not merely prove that a résumé exists.
Program pages
Explain the multidisciplinary team and what makes the program coherent. “Multidisciplinary” should mean more than photographs of several specialties arranged in a row.
Question content
Address second opinions, records, appointments, treatment logistics, caregiver questions, travel, insurance process and other practical concerns that often determine whether people move forward.
For organizations whose commercial problem is the laboratory itself, molecular testing, pathology services or scientific testing rather than the care program, my Laboratory Marketing page owns that adjacent market. For life-science companies commercializing therapies and platforms, Biotech & Life Sciences Marketing is the better home.
Trial visibility can be strategically important. Trial language also has zero room for creative optimism.
NCI describes cancer clinical trials as research studies that test approaches to prevention, diagnosis, treatment and supportive care. Its current search lets people look for NCI-funded trials and trials at NCI-Designated Cancer Centers supported by other organizations. NCI cancer clinical-trial information.
For a cancer center, trial discovery can support patients, families, referring physicians and research programs. The hard part is keeping the information current and useful. Trial status changes. Eligibility is specific. Tumor genetics can matter. Prior treatment can matter. Location can matter. A page that says “ask about exciting new trials” is essentially decorative.
I would connect trial pages to the official research source, investigator, disease program and the appropriate contact process. I would also make it clear that public information is not a determination of eligibility. NCI's advanced clinical-trial search itself requires details such as cancer type, stage, age, prior treatments, location and trial phase because eligibility is not a slogan.
Clinical-trial recruitment also appears as a sensitive-interest category in Google's personalized-advertising rules. Paid recruitment strategy should be reviewed against the current platform requirements and the study's own legal, ethical and research-governance requirements.
Oncology advertising can work. The targeting playbook is narrower for good reason.
High-intent paid search can be useful when somebody is actively looking for an oncologist, second opinion, cancer center, radiation program or specific disease expertise. Search also provides fast feedback about language and demand that can inform broader strategy.
But health is a sensitive-interest category under Google's current personalized-advertising rules. Google allows predefined audiences in sensitive categories while restricting advertiser-curated audiences such as Customer Match and data segments, with additional serving implications for some campaign types. Google's current health personalized-advertising policy.
That makes account design more important, not less. I care about query intent, match behavior, location, negatives, landing-page fit, call handling, conversion definition and privacy. I care much less about giving a black box permission to “find more people like these cancer patients.”
For broader paid, search, content, website and measurement execution outside the oncology-specific strategy, my Integrated Digital Marketing Services page covers the larger channel system.
A cancer website can contain some of the most sensitive intent on the internet. Treat the data accordingly.
Healthcare analytics deserves more thought than dropping familiar scripts onto every page and assuming the privacy policy will carry the moral weight.
HHS currently says HIPAA applies when information collected or disclosed through tracking technologies by a regulated entity includes protected health information. Its guidance also reflects the June 2024 federal court decision that vacated part of the earlier guidance concerning certain combinations of IP address and visits to unauthenticated public health webpages. Current HHS tracking-technology guidance.
The important point is not to turn that nuance into “pixels are fine” or “pixels are always illegal.” The analysis is fact-specific. What data is collected? On which page? What did the person submit? Where does it go? Is the organization a regulated entity? What permissions, agreements and safeguards apply? The privacy, security and legal team should make those determinations with accurate technical information.
I will never tell a cancer center that a plugin, server-side configuration or vendor logo magically makes the organization HIPAA compliant. Software can support a compliance program. Software is not a compliance program.
Oncology reputation lives in more places than a five-star widget can display.
Patients notice reviews, and review operations matter. But oncology reputation also moves through physicians, nurses, navigators, hospital affiliations, research, publications, community experience, advocacy groups, family stories and the way the office handles a frightening first phone call.
The specialty also punishes simplistic outcome narratives. Cancer biology differs. Stage differs. Comorbidity differs. Treatment goals differ. A patient can receive excellent care and still have a difficult outcome. Marketing should never use that complexity as an excuse to avoid quality information, but it should respect what the data actually means.
I want public claims to survive a conversation with the clinical team. If a sentence makes marketing excited and the oncologist nervous, the sentence is probably not finished.
“Cancer center,” “NCI-Designated” and “CoC accredited” are not interchangeable phrases.
Credentials matter because they help patients and referring physicians understand institutional capability. They also create an easy opportunity for sloppy copy.
The National Cancer Institute maintains a defined designation program for cancer centers. Separately, the American College of Surgeons Commission on Cancer accredits cancer programs under its Optimal Resources for Cancer Care standards. The CoC's current standards page states that the latest republication was released in March 2026. Commission on Cancer standards and resources.
Use the exact designation the institution currently holds and connect the claim to NCI's official information.
Describe the program's current accreditation accurately and avoid implying that accreditation predicts an individual outcome.
Verify program-specific certifications, accreditations and awards before turning them into public proof.
The marketing rule is refreshingly boring: if a credential can expire, change or apply only to one facility, verify it before publishing. Boring is underrated when the alternative is false.
Different cancers create different commercial questions because the medicine, referrals and patient journeys are different.
A cancer center can be tempted to solve content scale by making every disease page look alike. The result is efficient publishing and mediocre explanation. I would rather let the disease shape the page.
Screening, diagnostic imaging, breast surgery, medical oncology, radiation, reconstruction, genetics, high-risk programs and survivorship can all influence the journey. The patient may enter through an abnormal mammogram long before anyone searches for an oncologist.
Primary care, pulmonology, thoracic surgery, radiology, pathology, molecular testing, radiation and medical oncology may converge quickly. Screening and incidental findings create different entry points from symptomatic disease.
Gastroenterology, hepatobiliary surgery, colorectal surgery, medical oncology, radiation, interventional radiology and advanced endoscopy can create a regional referral network that looks nothing like a general oncology funnel.
Urology can remain central in prostate, bladder, kidney and testicular cancer journeys, which means the oncology program's growth is partly dependent on relationships with a specialty that may already own the patient relationship.
Leukemia, lymphoma and myeloma can require very specific disease expertise, infusion capability, cellular therapy or transplant relationships, trial awareness and long-term care. Search volume alone can badly understate referral value.
Sarcoma, neuroendocrine tumors, rare CNS disease and other uncommon cancers can pull patients across state lines. The public information has to earn that travel with credible subspecialty depth rather than adjectives about excellence.
I am interested in the commercial consequences of those differences. Which physician controls the first referral? Which service is scarce? Which patients travel? Which diagnosis benefits most from a second-opinion pathway? Where does pathology or molecular testing determine the next step? Which program needs local awareness and which needs national authority?
That is why a cancer service line should be organized around disease realities, not merely around the departments that happen to report to different vice presidents.
A second opinion is a different product from a first appointment, and the website should know that.
People seek oncology second opinions for many reasons: diagnostic confirmation, a difficult surgery, a rare cancer, uncertainty about treatment options, access to a subspecialist, concern about recurrence, interest in a trial or simply the need to hear the plan explained by another experienced team.
The person may already have a physician, pathology, imaging and a proposed treatment plan. That changes the digital experience. “Request an appointment” is often too vague. A second-opinion pathway can explain what records are needed, whether pathology or imaging review is part of the process, who determines physician fit, whether remote review is available where appropriate, how quickly the team usually responds and what happens if the recommendation is to continue care locally.
Geography matters here. A person may travel hundreds of miles for a one-time consultation or complex operation and then receive systemic therapy closer to home. A cancer center that understands hub-and-spoke relationships can market regional expertise without implying that every patient should relocate for every part of treatment.
NCI's current directory lets people search NCI-Designated Cancer Centers by state and learn about their research capabilities, programs and initiatives. That is a reminder that geography and institutional differentiation are already part of how people research cancer care. Find an NCI-Designated Cancer Center.
I would measure second opinions separately from ordinary new-patient inquiries. The source, diagnosis, travel radius, conversion to treatment, return-to-local-care relationship and referring physician can all tell leadership something useful about the center's actual market position.
Sometimes the person doing the research is not the patient.
Cancer redistributes work across families. One person is listening to the oncologist. Another is taking notes. Somebody else is trying to understand insurance. An adult child may be researching specialists from another state. A spouse may be comparing treatment locations at midnight while the patient is exhausted from hearing the word cancer all day.
That makes caregiver communication commercially relevant without reducing caregiving to a target segment. Clear location information, visit preparation, parking, lodging resources, contact paths, treatment schedules, support services and patient-education materials can remove friction for the people helping care happen.
The tone matters too. Oncology copy often lands at one of two extremes: sterile institutional language or emotional language that feels like it was focus-grouped within an inch of its life. People facing cancer do not need a website to perform empathy. They need the organization to communicate like competent humans who understand that the reader may be scared.
I prefer precise reassurance: explain what the team does, what information is needed, which questions can be answered now and which require a clinician. Give caregivers something useful to do. Make the next step visible. Avoid pretending that a warm paragraph can resolve uncertainty that medicine has not resolved.
Marketing cannot schedule an oncologist who does not exist.
Growth planning has to understand physician supply, APP support, nursing, infusion staffing, radiation therapists, physicists, dosimetrists, pharmacy, navigation, research coordinators and the administrative teams that move records, authorizations and referrals.
A program can have room in the infusion suite and no physician capacity. Another can recruit an excellent specialist but fail to create enough referral awareness around that person's actual disease focus. A third can have strong demand and still lose patients because navigation and authorization are overwhelmed.
Those are not all marketing problems, but marketing interacts with every one of them. If a new breast oncologist is joining, visibility strategy should begin before the first clinic day. If a radiation program has open capacity but two medical oncologists are full, demand generation needs to be selective. If a rare-disease specialist leaves, stale pages and advertising should not keep promising access that no longer exists.
For larger physician recruitment, retention and specialty-capacity questions, the adjacent Physician Staffing Consultant & Advisor work belongs in that conversation. The oncology page stays focused on how capacity changes growth strategy.
The same cancer program can have high demand and the wrong growth.
Oncology economics can involve physician access, infusion capacity, drug acquisition, buy-and-bill exposure, pharmacy operations, radiation equipment, hospital contracts, surgery, imaging, laboratory work, payer mix, authorization, site of care, research, advanced practice clinicians and increasingly complex value-based arrangements.
CMS's Enhancing Oncology Model is a current example of that shift. The model began in 2023, added a second cohort in 2025 and now runs through June 2030. CMS currently describes 23 physician group practices and more than 2,000 practitioners across more than 300 sites participating, with requirements that include patient navigation, care plans, social-needs screening and quality/data reporting. CMS Enhancing Oncology Model.
I would never use one payment model as a proxy for the entire oncology economy. I would use it as evidence that the business of cancer care increasingly connects treatment, coordination, quality, patient experience, utilization and data in ways a marketing dashboard should at least understand.
Marketing becomes much more intelligent when it knows the difference between “more cancer patients” and “more of the patients this program is designed, staffed and clinically appropriate to serve.”
The dashboard should know something about care, capacity and referral source.
Qualified organic visibility, local discovery, AI referrals, branded demand, physician-name searches and paid search.
Calls, secure inquiries, second-opinion requests, referral submissions and disease-program engagement.
Reached patients, records completion, scheduled new patients, time to appointment and appropriate triage.
Disease type, physician, service, location, referral source, geography, payer context and program priority where lawful and appropriate.
No-shows, wait time, call abandonment, referral leakage, authorization friction and capacity constraints.
New-patient value, program growth, downstream care, acquisition efficiency and revenue measures leadership can responsibly use.
Attribution in healthcare is rarely neat. A patient can see an oncologist's name in an AI answer, ask a primary-care physician about the doctor, read reviews, visit three pages, call the cancer center and later appear in the CRM as “phone.” That does not make the earlier touchpoints imaginary. It means measurement has to tolerate human behavior.
A dashboard without context can still be beautifully color-coded. That is not the same thing as insight.
A regional cancer group has 22 physicians, strong traffic and a problem nobody can see in Google Analytics.
This is a hypothetical example, not a client story.
The group has medical oncology, hematology, infusion and radiation across six locations. Organic traffic grew 24 percent. Paid search generates a healthy number of calls. Leadership wants another 20 percent in new patients.
Then the operating review changes the story.
- The busiest breast oncologist is booking six weeks out.
- The newest location has infusion capacity but weak local physician relationships.
- Radiation oncology has available starts, but its service pages are buried under the health-system domain.
- Myeloma referrals are leaving the market because subspecialty expertise is almost invisible online.
- Call tracking labels every caller as a lead even when the patient needs a different specialty.
- Navigation spends hours chasing incomplete outside records because the website never explains what is needed.
The answer is not “increase the ad budget 20 percent.” I would redirect the growth system: strengthen the underused location, deepen disease and physician authority where real expertise exists, improve radiation discovery, create a better records pathway, segment calls by appropriateness and preserve the overbooked physician's reputation without manufacturing demand that cannot be served.
That is oncology growth strategy. The channel is the last interesting part.
I do not want several Paper Boat Media pages answering the same healthcare question.
This page owns oncology-practice growth, cancer-center discovery, disease programs, cancer referrals, patient navigation, second opinions, oncology search, AI discovery and oncology-specific commercial strategy.
Owns the broader question of marketing physicians, surgeons, specialty practices and medical groups across many specialties.
Owns enterprise care-delivery strategy, system reputation, service-line portfolios, hospitals, health systems and institution-wide growth.
Remains the parent industry resource connecting oncology to the larger medical and healthcare ecosystem.
That separation matters to readers as much as search engines. A person looking for a cancer-program strategist deserves a page about oncology, not a broad healthcare page wearing a different H1.
Intelligence in healthcare marketing is mostly the discipline to notice what the channel cannot fix.
Marketing people are naturally attracted to things they can change quickly: copy, ads, pages, bids, emails, dashboards. Oncology forces a wider view. If the physician is full, the referral process is broken, records take ten days, a navigator is covering three jobs or the program has no coherent answer to “why this center for this disease,” media optimization is operating downstream of the real constraint.
I like the difficult version of the problem. I want to understand the service line, referral map, capacity, patient journey, disease mix, competitive set, technology, economics and clinical boundaries before deciding what marketing should do.
That does not make the work less creative. It makes the creativity more useful.
When the problem crosses search, content, analytics, positioning and executive prioritization, I can work across the pieces directly. When it crosses into medicine, law, privacy, reimbursement or research governance, I want the right professionals at the table. Knowing where expertise ends is part of expertise.
Oncology marketing, cancer-center growth, referrals, search and AI FAQs
What does an oncology marketing consultant actually do?
I help oncology practices, cancer centers and cancer programs connect positioning, physician authority, referral growth, search visibility, AI discovery, paid media, patient navigation, website experience and measurement to the way cancer care is actually delivered. The work starts with the business and care-delivery problem, not with a predetermined channel.
Do you work with medical oncology practices?
Yes. Medical oncology brings a distinctive mix of physician referrals, systemic therapy, infusion operations, payer realities, pharmacy economics, navigation and long-term patient relationships. Strategy has to understand that operating model before trying to increase demand.
Do you work with radiation oncology?
Yes. Radiation oncology can involve physician referrals, multidisciplinary treatment planning, technology-intensive positioning, geographic convenience and a very different capacity model from a medical oncology clinic. The marketing should explain expertise and access without turning equipment into a substitute for clinical judgment.
Do you work with surgical oncology programs?
Yes. Surgical oncology often sits at the intersection of organ-specific expertise, hospital relationships, multidisciplinary care, second opinions and regional referral patterns. The specialist page should make the surgeon, disease focus, program relationships and next step clear without making unsupported outcome claims.
Can you help a cancer center grow physician referrals?
Yes. Referral growth can include referrer research, physician and program positioning, service-line clarity, referral pathways, outreach support, relationship intelligence, content for professional audiences and better feedback loops. Referral strategy should be coordinated with physician leadership and operations rather than treated as a mailing-list exercise.
Can you help an oncology practice attract more patients through search?
Yes. Search can support cancer-type pages, physician discovery, second opinions, location visibility, treatment education and questions people ask after a diagnosis. The objective is qualified discovery and clearer access, not simply more traffic.
How does AI search change oncology marketing?
Patients and families increasingly ask search engines and AI systems detailed questions in conversational language. An oncology organization needs accurate, well-structured public information about diseases, specialists, services, locations, referrals and access so answer systems can understand the organization without inventing certainty that the clinical team did not provide.
Do you optimize for ChatGPT, Gemini and other AI answer systems?
I can improve the public information and authority signals that make an organization easier for modern answer systems to understand and cite. No consultant can guarantee placement in a specific AI answer, but clearer entities, deeper useful content, strong source relationships and technically accessible pages improve the underlying conditions for discovery.
Can oncology PPC and Google Ads still be useful?
Yes, but oncology is sensitive health content and targeting options are restricted. Paid search can still be useful for high-intent service and location queries when account structure, landing pages, claims, conversion tracking and privacy are handled carefully.
Can you use remarketing audiences for cancer patients?
Google treats health as a sensitive-interest category and restricts advertiser-curated audience targeting for sensitive health content. Campaign design should follow the current platform rules and the organization's legal and privacy requirements rather than assuming ordinary ecommerce tactics transfer cleanly into oncology.
Do you provide HIPAA compliance advice?
No. I can identify where tracking, forms, analytics, advertising technology and patient information create marketing and privacy questions, but legal and compliance determinations belong with the organization's qualified privacy, security and legal professionals. Technology does not automatically make an organization HIPAA compliant.
Can you help with cancer clinical trial visibility?
Yes, on the communication and discovery side. Trial information should be current, precise and connected to the appropriate research team, eligibility process and official trial resources. Marketing should never imply that a patient qualifies for a study or that an experimental treatment is established care.
Should a cancer center publish every clinical trial as a separate page?
Sometimes, but not automatically. The right approach depends on the research program, trial volume, data source, update process and how patients and referring physicians search. A stale trial page is worse than no trial page because status and eligibility can change.
Can you market an NCI-Designated Cancer Center differently?
Yes, because a verified NCI designation is a meaningful institutional signal tied to research capabilities and programs. It should be described accurately and only when the organization actually holds the designation. NCI designation, Commission on Cancer accreditation and other credentials are distinct and should not be blurred together.
Can you help a Commission on Cancer accredited program communicate its accreditation?
Yes. Accreditation can be an important trust and quality signal when described accurately. The public language should match the program's actual status and avoid implying that accreditation guarantees an individual clinical outcome.
How should oncology websites talk about survival rates and outcomes?
Very carefully. Outcome data can be meaningful, but the population, time period, case mix, endpoint and source matter. I would not turn an isolated statistic into a promotional promise. Clinical leadership, quality teams and appropriate reviewers should govern public outcome claims.
Can you help with second-opinion marketing?
Yes. Second opinions can be strategically important in oncology because patients may be evaluating diagnosis, treatment options, subspecialty expertise, clinical trials or a complex surgery. The page should explain who the service is for, what records are needed, how quickly the process moves and what happens next.
What should a cancer center website make easiest to find?
The right specialist, disease program, location, referral process, second-opinion route, appointment contact, records requirements, accepted coverage information where appropriate, support services and credible patient education. A person dealing with cancer should not have to reverse-engineer the health system's org chart.
Do patient navigators affect marketing performance?
Absolutely. Navigation is an operational function, but it can change whether interest becomes care. A growth strategy that generates inquiries while patients get lost between diagnosis, records, referrals, authorizations and scheduling is measuring the wrong victory.
Can you help community oncology practices compete with large academic centers?
Yes, but the strategy should be based on the practice's real strengths. Those may include access, convenience, continuity, physician relationships, infusion experience, community presence, selected subspecialty expertise or coordination with tertiary centers. Trying to imitate an academic cancer center is rarely the most credible position.
Can you help academic cancer centers with marketing?
Yes, particularly around program positioning, physician and investigator authority, clinical-trial discovery, disease-specific visibility, second opinions, regional and national reach, AI search, content governance and clearer pathways between research and patient-facing information.
How should oncology organizations measure marketing?
I would connect channel metrics to meaningful operating outcomes such as qualified inquiries, referral sources, new-patient access, second-opinion requests, program mix, downstream scheduling, capacity, geography and revenue where appropriate. Traffic alone can look impressive while telling leadership almost nothing about whether the cancer program is growing well.
Do you work with oncology practices outside Florida?
Yes. Paper Boat Media is based in DeLand, Florida, and I work nationally. Oncology referral patterns, competition, health-system relationships, demographics and payer conditions are local, so the strategy should be grounded in the market even when the advisory work is handled remotely.
Are you a physician or cancer clinician?
No. I am a marketing, AI-search, growth and business strategist. I do not diagnose cancer, recommend treatment or replace clinical, legal, compliance, billing or regulatory professionals. My job is to understand the commercial and communication system around care well enough to make the strategy more intelligent.
What is the best first project for an oncology practice or cancer center?
Usually a focused growth and discovery audit is the best starting point. I want to understand the service mix, physicians, referral patterns, capacity, website, search visibility, AI visibility, paid media, access points, reputation, analytics and current growth constraint before prescribing a campaign.
Tell me what is happening, what should be happening instead, and where the system feels stuck.
Maybe referrals have flattened. Maybe a strong disease program is nearly invisible. Maybe paid media is generating the wrong calls. Maybe a new center needs a regional growth strategy. Maybe AI search has changed discovery. Maybe the real problem is access, capacity or navigation and marketing keeps getting blamed because it owns the dashboard.
I am comfortable beginning before the problem has been named perfectly. That is often the useful part.